By Andy Acker, CFA & Luyi Guo, Ph.D., CFA & Rich Carney, CFA
Last week, the Trump administration abandoned plans to overhaul drug rebates in Medicare while a federal judge ruled against listing prescription drug prices in TV ads. But U.S. drug reform is far from over, with implications for investors, says Portfolio Manager Andy Acker and Health Care Research Analysts Luyi Guo and Rich Carney.
The road to drug pricing reform in the U.S. continues to take some surprising turns. Last week, President Trump abandoned a plan to overhaul drug rebates in Medicare after